Fenofibrate inhibits the growth of prostate cancer through regulating autophagy and endoplasmic reticulum stress

Biochem Biophys Res Commun. 2018 Sep 18;503(4):2685-2689. doi: 10.1016/j.bbrc.2018.08.024. Epub 2018 Aug 8.

Abstract

Fenofibrate is a fibric acid derivative which exhibits a role of peroxisome proliferator-activated receptor-alpha agonist. It is widely utilized in therapy of hyperlipidemia and hypercholesterolemia. Its anticancer function is discovered in recent years. However, the role of fenofibrate in prostate cancer (PCa) is poorly understood. In this study, we investigated the function and mechanism of fenofibrate in PCa cells. Firstly, fenofibrate treated PCa cells showed more apoptosis compared with the control group. Further, we found that fenofibrate induced autophagy but finally blocked its complete flux in PCa cells through regulating AMPK-mTOR pathway. The intermediate metabolite from uncompleted autophagy induced endoplasmic reticulum stress (ER stress) via PERK and IRE1 signalings. In vivo mice model confirmed that fenofibrate inhibited the growth of PCa. This study suggests that fenofibrate is an effective inhibitor of PCa by regulating autophagy and ER stress.

Keywords: Autophagy; Endoplasmic reticulum stress; Fenofibrate; Prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / genetics
  • AMP-Activated Protein Kinases / metabolism
  • Animals
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Autophagy / drug effects*
  • Cell Proliferation
  • Endoplasmic Reticulum Stress / drug effects*
  • Endoribonucleases / genetics
  • Endoribonucleases / metabolism
  • Fenofibrate / pharmacology*
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Hypolipidemic Agents / pharmacology
  • Male
  • Mice
  • PC-3 Cells
  • PPAR alpha / antagonists & inhibitors
  • PPAR alpha / genetics
  • PPAR alpha / metabolism
  • Prostate / drug effects
  • Prostate / metabolism
  • Prostate / pathology
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology
  • Protein Serine-Threonine Kinases / genetics
  • Protein Serine-Threonine Kinases / metabolism
  • Signal Transduction
  • TOR Serine-Threonine Kinases / genetics
  • TOR Serine-Threonine Kinases / metabolism
  • Tumor Burden / drug effects
  • Xenograft Model Antitumor Assays
  • eIF-2 Kinase / genetics
  • eIF-2 Kinase / metabolism

Substances

  • Antineoplastic Agents
  • Hypolipidemic Agents
  • PPAR alpha
  • MTOR protein, human
  • EIF2AK3 protein, human
  • ERN1 protein, human
  • Protein Serine-Threonine Kinases
  • TOR Serine-Threonine Kinases
  • eIF-2 Kinase
  • AMP-Activated Protein Kinases
  • Endoribonucleases
  • Fenofibrate